Physician profile
Maria Guzman
NPI 1750564969
$1,190.44
in general payments reported to CMS, 2019-2025
15 companies · $126 in 2025
The $126 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.28 · 2023: $704 · 2024: $284 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $273.47 | 2023-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $255.04 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.61 | 2023-2024 | Breztri, Farxiga |
| Ensodata, INC. | $154.29 | 2023 | |
| Exact Sciences Corporation | $79.63 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $37.09 | 2023 | Xarelto |
| Harmony Biosciences LLC | $22.75 | 2022 | |
| Glaxosmithkline, LLC. | $22.47 | 2023 | Shingrix, Arexvy |
| Lilly USA, LLC | $22.40 | 2024 | Jardiance |
| Pfizer INC. | $21.41 | 2025 | |
| Edwards Lifesciences Corporation | $19.94 | 2022 | |
| Corium, LLC | $16.17 | 2023 | Adlarity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.12 | 2023 | Jardiance |
| Inspire Medical Systems, INC. | $15.40 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.65 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.